D. T.: Oral carbohydrate tolerance tests. Arch. Int. Med. *113*:641-48, May 1964.

[3] Allen, F. M.: Experimental studies on diabetes. II. Effect of carbohydrate diets. J. Exp. Med. *31*:395-402, April 1920.

[4] Conn, J. W., and Newberg, L. H.: The glycemic response to isoglucogenic quantities of protein and carbohydrate. J. Clin. Invest. *15*:665-71, Nov. 1936.

[5] Swan, D. C., Davidson, P., and Albrink, M.: Effect of simple and complex carbohydrates on plasma nonesterified fatty acids, plasma-sugar and plasma-insulin during oral carbohydrate tolerance tests. Lancet *1*:60-63, Jan. 1966.

RONALD L. SEARCY, PH.D.
EDMUND M. Y. LOW, M.D.

From the Departments of Pathology, University of California, California College of Medicine, Los Angeles, California, and the Los Angeles County General Hospital (Unit 2), Los Angeles, California. Dr. Searcy's present address: Research Division, Hoffmann-La Roche, Inc., Nutley, New Jersey 07110.

To the Editor: Drs. Searcy and Low have presented a convincing review of the literature which showed that oral glucose produced greater degrees of hyperglycemia than did carbohydrate containing meals especially when these meals also contained protein and fat. The error in their theoretical argument against our published work is that although the above statement is correct, the digestion of these foods is entirely different from that of corn syrup—which is not starch—but a completely soluble partially hydrolyzed starch. They speculate that some individuals, particularly in the older age groups, digest carbohydrate at less than optimal rates but the reference quoted to substantiate this speculation does not contain such data. More important, however, are the actual experimental comparisons between glucose and the *partially hydrolyzed* starch solution (Glucola) in which the resulting blood glucose curves were shown to be virtually identical.[1]

It is of interest that this new carbonated glucose tolerance solution has now been used in 250,000 individuals in the detection program conducted by the Diabetes Association of Greater Cleveland. Of the individuals over the age of sixty, 15 per cent screened positive using the criterion of a blood glucose of 140 mg. per 100 ml. two hours after the loading dose.

REFERENCE

[1] Leonards, J. R., McCullagh, E. P., and Christopher, T.: Diabetes *14*:96-99, Feb. 1965.

JACK R. LEONARDS, M.D., PH.D.
Western Reserve University
Cleveland, Ohio
E. P. MCCULLAGH, M.D.
Cleveland Clinic
Cleveland, Ohio

ABSTRACTS

Arquilla, Edward R.; Ooms, Henri; and Finn, Jack (Dept. of Pathology, Univ. of Calif., Sch. of Med., Los Angeles): GENETIC DIFFERENCES OF COMBINING SITES OF INSULIN ANTIBODIES AND IMPORTANCE OF C-TERMINAL PORTION OF THE A CHAIN TO BIOLOGICAL AND IMMUNOLOGICAL ACTIVITY OF INSULIN. Diabetologia 2:1-13, 1966.

Verbatim Summary. Using an insoluble insulin complex, it was possible to demonstrate that antibodies to insulin produced in individual animals are directed towards different portions of the insulin molecule. Furthermore, using the antisera from two different inbred strains of guinea pigs and their F_1 and F_2 offspring, evidence is presented for the genetic control of combining site configurations of antibodies to insulin produced in guinea pigs. The importance of different portions of the insulin molecule to biological and immunological activity was investigated. The attachment of I-125 to insulin (reportedly to the tyrosines at positions fourteen and/or nineteen of the A chain) seems to impair both the biological and immunological activity of insulin. The distribution of antibody-bound and free I-125-insulin was found to be different from the distribution of nonlabeled insulin. Relatively pure I-125-insulin was separated from nonlabeled insulin by acrylamide gel electrophoresis, and was found to have markedly reduced immunological reactivity in the immune hemolysis inhibition assay. It was concluded that antibodies to insulin exist which cannot react with iodinated insulin. Furthermore, when tested in the rat adipose tissue assay, purified I-125-insulin preparations had little or no biological activity. Conversely, mono-substituted fluorescein-labeled insulin (purified on acrylamide gel electrophoresis) appears to retain full immunological and biological competence. Fluorescein is thought to attach to the N-terminal phenylalanine of the B chain and/or to the N-terminal glycine of the A chain. It is concluded that these two residues contribute little to the biological and immunological integrity of insulin. Studies of this nature aid in elucidating the surface configuration of insulin, and thereby may contribute to an understanding of its tertiary structure.

Behrman, Simon (London, England): RETINAL CIRCULATION (Correspondence). Brit. Med. J. *1*:800, March 26, 1966.

The author takes issue with the argument that gradual reduction in arterial supply to the eye may be responsible for the classic ophthalmoscopic picture of central retinal vein obstruction (Editorial. "Retinal Circulation" Brit. Med. J. *1*: 562, 1966), and a recent review of changes in retinal veins in response to "chronic ischemia" is cited (Knox, D. L.: Amer. J. Ophthal. 60:995, 1965) in which the results of ischemia